Epidemiology, diagnosis, and treatment patterns of prostate cancer in Algeria

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a descriptive, cross-sectional observational study enrolling up to 500 patients with histologically and/or biologically confirmed prostate cancer who are followed at participating centers in Algeria. Data are collected from medical records and a structured ~30-minute patient interview and entered into a standardized electronic case report form to ensure completeness. The study records sociodemographic details, medical history, clinical and biological disease features, diagnostic tests performed, and therapeutic strategies used. All data are anonymized and used solely for research purposes to characterize current practice patterns and outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients aged 19 years and older.
* Diagnosis of prostate cancer confirmed histologically and/or biologically.
* Patients followed in the participating oncology departments.
* Written informed consent obtained.

Non Inclusion Criteria:

* Histological types other than carcinoma
* Secondary tumors
* Participation in an interventional study

Where it's running

• CAC BLIDA - Oncology Department
  Algiers, Algeria, Algeria Recruiting
• Centre Pierre et Marie Curie - Oncology Department
  Algiers, Algeria, Algeria Recruiting
• Centre Pierre et Marie Curie - Radiology Department
  Algiers, Algeria, Algeria Recruiting
• CHU Bab El Oued
  Algiers, Algeria, Algeria Recruiting
• CHU Béni Messous - Oncology Departement
  Algiers, Algeria, Algeria Recruiting
• EPH ROUIBA - Oncology Department
  Algiers, Algeria, Algeria Recruiting

Study contacts

• Study coordinator: BOUNEDJAR ADDA, Professor
• Email: a_bounedjar@yahoo.fr
• Phone: +213 25 20 90 72

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early postoperative PSA after prostate removal as a predictor of cancer outcomes

  We will test whether early PSA levels after prostate removal can help predict long-term cancer outcomes in men undergoing radical prostatectomy.

  Recruiting Lithuanian University of Health Sciences · Kaunas, Kauno · NCT07516886

• FK-PC101 vaccine for men with high-risk prostate cancer after surgery

  This study is testing a new vaccine for men with high-risk prostate cancer after surgery to see if it can help prevent the cancer from coming back.

  Recruiting at 2 sites Phase 2 Cellvax Therapeutics Inc · Chicago, Illinois and 2 other locations · NCT06636682

• Adaptive intraoperative biopsy system for prostate cancer using imaging and metabolic feedback

  Aiming to test a smart biopsy approach that combines preoperative imaging with real-time metabolic signals to guide where to take prostate biopsy cores for better precision in men suspected of prostate cancer.

  Recruiting at 4 sites Shanghai Zhongshan Hospital · Shanghai and 3 other locations · NCT07856017

• MRT-2359 plus apalutamide in advanced prostate cancer

  This Phase 2 trial tests whether taking MRT-2359 with apalutamide can lower PSA in men with castration-resistant prostate cancer.

  Recruiting at 7 sites Phase 2 Monte Rosa Therapeutics, Inc · Los Angeles, California and 13 other locations · NCT07745361

• Using new non-contrast MRI sequences to improve diagnosis and grading of prostate cancer

  This project tries new non-contrast MRI scans to see if they improve diagnosis and grading for men with suspected prostate cancer and elevated PSA.

  Recruiting The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07552285

• LaserSAFE: Quick in OR imaging to check margins during prostatectomy

  A new in‑the‑operating‑room imaging method called LaserSAFE is tested to see if it can quickly detect cancer at the edge of the prostate during surgery for patients undergoing robot-assisted prostatectomy.

  Recruiting University College, London · London · NCT07541911

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.